# XOLREMDI® (mavorixafor) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mavorixafor

> The FDA approved XOLREMDI® (mavorixafor), sponsored by X4 Pharmaceuticals, Inc (XFOR), on December 31, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is XOLREMDI® (mavorixafor) FDA approved?

Yes. The FDA approved XOLREMDI® (mavorixafor), sponsored by X4 Pharmaceuticals, Inc (XFOR), on December 31, 2024. SEC Form 10-K: "For the year ended December 31, 2024, a $7.0 million regulatory milestone payment was incurred and paid after receipt of FDA approval of the Company's NDA on April 26, 2024." [Calendar and source filings](https://sec-api.dev/pdufa/mavorixafor)

Source: SEC Form 10-K, accession 0001628280-25-014805, https://www.sec.gov/Archives/edgar/data/1501697/000162828025014805/xfor-20241231.htm (retrieved 2026-11-12). Last confirmed 2025-03-26. Cite: https://sec-api.dev/pdufa/mavorixafor#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | XOLREMDI® (mavorixafor) |
| Codes | AMD11070 |
| Sponsor | X4 Pharmaceuticals, Inc (XFOR) https://sec-api.dev/companies/xfor/catalysts |
| Indications | cn, we expect, people aged 12 years and older with whim syndrome, [Neutropenia](https://sec-api.dev/indications/neutropenia), WHIM Syndrome, Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders |
| Modality |  |
| FDA designations | accelerated, breakthrough, fast track, orphan |

## Timeline

### December 31, 2023: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: people aged 12 years and older with WHIM syndrome.
- First seen 2025-03-26, last confirmed 2025-03-26.
- SEC Form 10-K (accession 0001628280-25-014805): "For the year ended December 31, 2023, a $5.0 million milestone was incurred and paid upon the FDA's acceptance of the Company's NDA seeking approval of oral, once-daily mavorixafor in the treatment of people aged 12 years and older with WHIM syndrome." https://www.sec.gov/Archives/edgar/data/1501697/000162828025014805/xfor-20241231.htm

### April 29, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: CN, we expect.
- First seen 2024-11-13, last confirmed 2026-03-17.
- SEC Form 10-Q (accession 0001628280-25-039327): "On April 29, 2024, the Company announced that the U.S. Food and Drug Administration ("FDA") approved the Company's New Drug Application ("NDA") for mavorixafor, which is being marketed in the U.S. under the trade name XOLREMDI®, for use as an oral, once-daily therapy in patients 12 years of age and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis), to increase the number of circulating mature neutrophils and lymphocytes." https://www.sec.gov/Archives/edgar/data/1501697/000162828025039327/xfor-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-039327): "On April 29, 2024, we announced that the U.S. FDA approved our NDA for mavorixafor, which is being marketed in the U.S. under the trade name XOLREMDI, for use as an oral, once-daily therapy in patients aged 12 years of age and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, to increase the number of circulating mature neutrophils and lymphocytes." https://www.sec.gov/Archives/edgar/data/1501697/000162828025039327/xfor-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-021358): "On April 29, 2024, the Company announced that the U.S. Food and Drug Administration ("FDA") approved the Company's New Drug Application ("NDA") for mavorixafor, which is being marketed in the U.S. under the trade name XOLREMDI®, for use as an oral, once-daily therapy in patients 12 years of age and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis), to increase the number of circulating mature neutrophils and lymphocytes." https://www.sec.gov/Archives/edgar/data/1501697/000162828025021358/xfor-20250331.htm
- SEC Form 10-Q (accession 0001628280-25-021358): "On April 29, 2024, we announced that the U.S. FDA approved our NDA for mavorixafor, which is being marketed in the U.S. under the trade name XOLREMDI, for use as an oral, once-daily therapy in patients aged 12 years of age and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, to increase the number of circulating mature neutrophils and lymphocytes." https://www.sec.gov/Archives/edgar/data/1501697/000162828025021358/xfor-20250331.htm
- SEC Form 10-K (accession 0001628280-25-014805): "On April 29, 2024, we announced that the U.S. FDA approved our NDA for mavorixafor, which is being marketed in the U.S. under the trade name XOLREMDI, for use as an oral, once-daily therapy in patients aged 12 years of age and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, to increase the number of circulating mature neutrophils and lymphocytes." https://www.sec.gov/Archives/edgar/data/1501697/000162828025014805/xfor-20241231.htm
- SEC Form 10-K (accession 0001628280-25-014805): "On April 29, 2024, the Company announced that the FDA approved the Company's New Drug Application ("NDA") for mavorixafor, which is being marketed in the U.S. under the trade name XOLREMDI®, for use as an oral, once-daily therapy in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), to increase the number of circulating mature neutrophils and lymphocytes." https://www.sec.gov/Archives/edgar/data/1501697/000162828025014805/xfor-20241231.htm
- SEC Form 10-Q (accession 0001628280-24-047445): "On April 29, 2024, the Company announced that the FDA approved the Company's New Drug Application ("NDA") for mavorixafor, which is being marketed in the U.S. under the trade name XOLREMDI, for use as an oral, once-daily therapy in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), to increase the number of circulating mature neutrophils and lymphocytes." https://www.sec.gov/Archives/edgar/data/1501697/000162828024047445/xfor-20240930.htm
- SEC Form 10-Q (accession 0001628280-24-047445): "On April 29, 2024, we announced that the U.S. FDA approved our NDA for mavorixafor, which is being marketed in the U.S. under the trade name XOLREMDI, for use as an oral, once-daily therapy in patients aged 12 years of age and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, to increase the number of circulating mature neutrophils and lymphocytes." https://www.sec.gov/Archives/edgar/data/1501697/000162828024047445/xfor-20240930.htm
- SEC Form 10-K (accession 0001501697-26-000018): "As a result of the April 2024 FDA approval of XOLREMDI and the continued expansion of our clinical development activities to support our 4WARD trial and, following the completion of the 4WARD trial, the potential commercial launch of mavorixafor for patients with CN, we expect that our manufacturing, distribution and related operational requirements will increase correspondingly." https://www.sec.gov/Archives/edgar/data/1501697/000150169726000018/xfor-20251231.htm
- SEC Form 10-K (accession 0001628280-25-014805): "In April 2024, we received FDA approval of mavorixafor, which is being marketed in the U.S. under the trade name XOLREMDI, for use as an oral, once-daily therapy in patients 12 years of age and older with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes." https://www.sec.gov/Archives/edgar/data/1501697/000162828025014805/xfor-20241231.htm

### December 31, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-26, last confirmed 2025-03-26.
- SEC Form 10-K (accession 0001628280-25-014805): "For the year ended December 31, 2024, a $7.0 million regulatory milestone payment was incurred and paid after receipt of FDA approval of the Company's NDA on April 26, 2024." https://www.sec.gov/Archives/edgar/data/1501697/000162828025014805/xfor-20241231.htm

### December 23, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: WHIM Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03995108 (Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-23 (ACTUAL); Lead Sponsor X4 Pharmaceuticals." https://clinicaltrials.gov/study/NCT03995108

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-03-25, last confirmed 2025-05-01.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-021304): "Top-line 4WARD data expected in 2H 2026 NEXT VALUE DRIVERS: LARGER INDICATION OF CHRONIC NEUTROPENIA & TARGETED EUROPEAN WHIM APPROVAL" https://www.sec.gov/Archives/edgar/data/1501697/000162828025021304/ex_992xx4updatedinvestor.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-014601): "With a large number of sites now activated and global screening ongoing, we expect full trial enrollment in the third or fourth quarter of this year and top-line trial data in the second half of 2026."" https://www.sec.gov/Archives/edgar/data/1501697/000162828025014601/a991earningsreleasedatedma.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-021304): "◦X4 continues to expect full enrollment in the trial in the third or fourth quarter of 2025, and disclosure of top-line data in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1501697/000162828025021304/a991earningsreleasedatedma.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-014601): "full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026" https://www.sec.gov/Archives/edgar/data/1501697/000162828025014601/a991earningsreleasedatedma.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-014601): "Enrollment Update: Given the average screening rates currently observed, the company expects the trial to be fully enrolled in the third or fourth quarter of 2025, and disclosure of top-line data in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1501697/000162828025014601/a991earningsreleasedatedma.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-021304): "4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026" https://www.sec.gov/Archives/edgar/data/1501697/000162828025021304/a991earningsreleasedatedma.htm

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Neutropenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06056297 (A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor X4 Pharmaceuticals." https://clinicaltrials.gov/study/NCT06056297

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Neutropenia.
- First seen 2026-03-17, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06056297 (A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor X4 Pharmaceuticals." https://clinicaltrials.gov/study/NCT06056297
- SEC Form 10-K (accession 0001501697-26-000018): "We expect to complete enrollment in the third quarter of 2026 and report top-line data results in the second half of 2027, with the goal of receiving FDA approval in 2028." https://www.sec.gov/Archives/edgar/data/1501697/000150169726000018/xfor-20251231.htm
- SEC Form 10-K (accession 0001501697-26-000018): "We are targeting completion of enrollment in 4WARD in the third quarter of 2026 and expect to provide top-line data from our 4WARD trial in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1501697/000150169726000018/xfor-20251231.htm

### Q1 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-09-09, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001501697-26-000084): "Top-line pivotal Phase 3 study in Primary Chronic Neutropenia data expected in Q1 2028" https://www.sec.gov/Archives/edgar/data/1501697/000150169726000084/ex991_x4presentation.htm
- Press release filed with the SEC (EX-99) (accession 0001501697-26-000084): "Topline 4WARD Phase 3 data expected in Q1 2028; approval anticipated late 2028/early 2029" https://www.sec.gov/Archives/edgar/data/1501697/000150169726000084/ex991_x4presentation.htm
- Press release filed with the SEC (EX-99) (accession 0001501697-26-000076): "Top-line pivotal Phase 3 study in Chronic Neutropenia data expected in H1 2028" https://www.sec.gov/Archives/edgar/data/1501697/000150169726000076/x4pharmaceuticalscorpora.htm
- Press release filed with the SEC (EX-99) (accession 0001501697-26-000084): "Endpoints powered to 93% and 89%, respectively, for the ITT population Secondary Endpoints: Severity and duration of infection, antibiotic use, fatigue, QoL, and safety Full enrollment (N-126) expected Q4 2026 with top-line data expected Q1 2028" https://www.sec.gov/Archives/edgar/data/1501697/000150169726000084/ex991_x4presentation.htm
- Press release filed with the SEC (EX-99) (accession 0001501697-26-000076): "Topline data expected in H1 2028" https://www.sec.gov/Archives/edgar/data/1501697/000150169726000076/x4pharmaceuticalscorpora.htm
- Press release filed with the SEC (EX-99) (accession 0001501697-26-000076): "Topline data expected in H1 2028; approval anticipated late 2028/early 2029" https://www.sec.gov/Archives/edgar/data/1501697/000150169726000076/x4pharmaceuticalscorpora.htm
- Press release filed with the SEC (EX-99) (accession 0001501697-26-000084): "Topline data expected in Q1 2028" https://www.sec.gov/Archives/edgar/data/1501697/000150169726000084/ex991_x4presentation.htm
- SEC Form 10-Q (accession 0001501697-26-000089): "The trial is designed to enroll approximately 25 patients, with the first participant expected to be enrolled in the first quarter of 2027 and top-line data expected in the first quarter of 2028." https://www.sec.gov/Archives/edgar/data/1501697/000150169726000089/xfor-20260930.htm

### late 2028: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-11-05, last confirmed 2025-11-05.
- Press release filed with the SEC (EX-99) (accession 0001501697-25-000041): "•With a strengthened cash runway to the end of 2028, X4 is now expected to be able to complete the 4WARD trial, file a potential sNDA for the chronic neutropenia indication, and, if successful, launch mavorixafor in this new indication by the end of 2028." https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/ex-991pressreleasenovember.htm

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07902830 (A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-01-30 (ESTIMATED); Lead Sponsor X4 Pharmaceuticals." https://clinicaltrials.gov/study/NCT07902830

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07902830 (A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-01-30 (ESTIMATED); Lead Sponsor X4 Pharmaceuticals." https://clinicaltrials.gov/study/NCT07902830

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mavorixafor.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "XOLREMDI® (mavorixafor) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mavorixafor

```bibtex
@misc{secapidev_pdufa_mavorixafor_20261116,
  title        = {XOLREMDI® (mavorixafor) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mavorixafor}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mavorixafor_20261116","title":"XOLREMDI® (mavorixafor) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mavorixafor","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
